Back to Screener

Healthcare

Caribou Biosciences, Inc.(CRBU)

Live Price

Offline

$1.68

+7.01% today

1Y Change

+31.75%

Window

Jun 30, 2025 โ†’ Jun 24, 2026

Market Cap
$190.00M
Revenue Growth
+11.7%
EPS Growth
+3.6%
Dividend Yield
0.0%

Coverage: 247 bars ยท Jun 30, 2025 โ†’ Jun 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Caribou Biosciences, Inc. (CRBU) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $1.68 and up 31.7% across the available one-year price window (Jun 30, 2025 โ†’ Jun 24, 2026). Baseline metrics include revenue growth of +11.7%, EPS growth of +3.6%, a dividend yield of 0.0%. What stands out right now is revenue +11.7%, EPS +3.6%, free cash flow +22.4% with operating margin -1329.4% and ROIC -95.1%. Valuation already assumes a fairly strong business story at price/sales 16.8. Stock Foundry combines CRBU price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

CRBU vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

Relative Read

Mixed setup vs SPY

CRBU is 13.07 pts ahead over the shared 1Y window.

CRBU had 41.92 pts deeper max drawdown than SPY.

CRBU beat SPY in 1 of 2 calendar years shown and trailed in 1.

CRBU

+31.75%

Normalized return

SPY

+18.68%

S&P 500

Excess Return

+13.07 pts

Relative to SPY

CRBU Max Drawdown

-51.06%

Trailing 1Y

SPY Max Drawdown

-9.13%

Trailing 1Y

CRBUSPY

Calendar-Year Returns

Uses the longest available daily history for CRBU and SPY.

YearCRBUSPYExcessLeader
2026+4.40%+6.71%-2.30 ptsSPY
2025+26.19%+11.19%+15.00 ptsCRBU

Unable to load analyst forecasts.

Timed out loading forecasts for CRBU

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.